Express News | Pharmather Holdings Ltd - Receipt of a Complete Response Letter ("Crl") for Its Priority Original Abbreviated New Drug Application for Ketamine
Moomoo 24/7Apr 18 16:00 ET
Express News | Pharmather Holdings Ltd: Has Completed Necessary Tests and Responses to Address Fda's Comments
Moomoo 24/7Apr 18 16:00 ET
PharmaTher Expects FDA to Decide on Ketamine Approval by April 29
Seeking AlphaJan 10 11:56 ET
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedeli
BenzingaOct 2, 2023 09:46 ET
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings' (OTCQB:PHRRF) new drug application for a racemic ketamine product.
BenzingaSep 27, 2023 14:38 ET
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. Top players featured include known names such as COMPASS Path
BenzingaSep 12, 2023 16:35 ET
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
Specialty biotech company PharmaTher Holdings (OTCQB:PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, to the F
BenzingaSep 6, 2023 17:21 ET
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal prose
BenzingaJul 24, 2023 17:14 ET
PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
PharmaTher Holdings (OTCQB:PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former's novel microneedle patch for the delivery of DMT, and research yielded positive outcomes. T
BenzingaJul 18, 2023 17:45 ET
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Psychedelics biotech BetterLife Pharma Inc. (OTCQB:BETRF) is fast-tracking its U.S. patent application covering the composition of matter, treatment uses and a novel production method of non-hallucino
BenzingaJun 28, 2023 15:01 ET
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB:PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic keta
BenzingaJun 27, 2023 18:05 ET
PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement
Psychedelics biotech PharmaTher Holdings (OTCQB:PHRRF) has entered into a collaborative partnership with pharma marketing company Vitruvias Therapeutics for the commercialization of its proprietary ra
BenzingaJun 20, 2023 22:38 ET
PharmaTher Seeks Fast Track FDA Approval for KETARX in Parkinson's Disease Treatment
Seeking AlphaMay 2, 2023 11:40 ET
PharmaTher (OTC:PHRRF) Trading 5.1% Higher
PharmaTher Holdings Ltd. (OTC:PHRRF – Get Rating) shot up 5.1% during trading on Wednesday . The stock traded as high as $0.11 and last traded at $0.11. 22,300 shares were traded during mid-day tradi
Defense WorldApr 6, 2023 03:02 ET
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin
BenzingaApr 5, 2023 09:58 ET
Ketamine Company Advances Parkinson's Treatment Through Final Stages Toward FDA Approval
PharmaTher Holdings Ltd. (OTCQB:PHRRF)'s recent meeting with the FDA on the feasibility of a Phase 3 program for proprietary ketamine KETARX to treat levodopa-induced dyskinesia in Parkinson's disease
BenzingaMar 30, 2023 13:38 ET
PharmaTher (OTC:PHRRF) Shares Up 12%
PharmaTher Holdings Ltd. (OTC:PHRRF – Get Rating)'s stock price shot up 12% on Wednesday . The stock traded as high as $0.13 and last traded at $0.12. 139,111 shares traded hands during mid-day tradin
Defense WorldMar 2, 2023 02:42 ET
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA an
BenzingaFeb 27, 2023 19:31 ET
Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind
Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB:LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTC:PHRRF) to evaluate the delivery of DMT through PharmaTh
Benzinga Real-time NewsFeb 22, 2023 13:44 ET
PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
Specialty ketamine company PharmaTher Holdings Ltd. (OTCQB:PHRRF) submitted its Type B meeting package to the FDA to discuss the remaining requirements for the KETARX on-body pump system and submit th
Benzinga Real-time NewsFeb 7, 2023 15:37 ET
No Data
No Data